Eton Pharmaceuticals (ETON) EV to EBITDA (2018 - 2026)

Eton Pharmaceuticals has disclosed EV to EBITDA across 9 years of filings, most recently posting 77.95 for Q2 2026.

• In Q2 2026, EV to EBITDA rose 132.23% year-over-year to 77.95; the TTM figure through Jun 2026 stood at 80.29 (up 118.16% YoY), while the FY2025 annual figure was 511.17, down 289.49% from the prior year.
• EV to EBITDA came in at 77.95 for Q2 2026 at Eton Pharmaceuticals, down from 175.09 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 541.86 in Q4 2024 to a low of 703.56 in Q1 2025.
• Average EV to EBITDA over 5 years is 37.73, with a median of 22.83 recorded in 2024.
• Year-over-year, EV to EBITDA sank 1028.8% in 2023 and jumped 1285.09% in 2024.
• Over 5 years, EV to EBITDA stood at 51.97 in 2022, then plunged by 187.98% to 45.72 in 2023, then soared by 1285.09% to 541.86 in 2024, then tumbled by 67.69% to 175.09 in 2025, then tumbled by 55.48% to 77.95 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 77.95 in Q2 2026, 175.09 in Q4 2025, and 400.31 in Q3 2025.